Nissim Darvish - 14 Jun 2023 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Role
Director
Signature
/s/ Matthew Rudolph, Esq., Attorney-in-Fact for Nissim Darvish
Issuer symbol
CMMB
Transactions as of
14 Jun 2023
Net transactions value
$0
Form type
4
Filing time
05 Jul 2023, 17:48:43 UTC
Previous filing
23 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CMMB American Depositary Shares 1,200 14 Jun 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMMB Option to Purchase American Depositary Shares Award $0 +20,572 $0.000000 20,572 14 Jun 2023 American Depositary Shares 20,572 $1.70 Direct F1, F2, F3
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6,857 $0.000000 6,857 16 Mar 2023 American Depositary Shares 6,857 $1.62 Direct F1, F2, F4
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6,820 $0.000000 6,820 07 Mar 2022 American Depositary Shares 6,820 $3.53 Direct F1, F2, F5
transaction CMMB Option to Purchase American Depositary Shares Award $0 +11,884 $0.000000 11,884 19 Apr 2021 American Depositary Shares 11,884 $27.26 Direct F1, F2, F6
transaction CMMB Option to Purchase American Depositary Shares Award $0 +10,123 $0.000000 10,123 28 Oct 2016 American Depositary Shares 10,123 $0.8000 Direct F1, F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F2 Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F3 These options vest and become exercisable in equal monthly installments over a 36 month period, subject to the Reporting Person's continued service.
F4 These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
F5 These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.
F6 These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
F7 The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.